Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into the second half of 2026 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

SOUTH SAN FRANCISCO - Aligos Therapeutics, Inc. (NASDAQ:ALGS), a company specializing in therapies for liver and viral diseases with a current market capitalization of $96.58 million, announced today ...

You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> PTC Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Aligos Therapeutics ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Aligos Therapeutics, Inc. (NASDAQ:ALGS – Get Free Report) saw a large increase in short interest in the month of December.As of December 31st, there was short interest totalling 597,300 shares ...

Check the time stamp on this data. Updated AI-Generated Signals for Aligos Therapeutics Inc. (ALGS) available here: ALGS.

As you can see from the chart above the percentage of shares that are sold short for Aligos Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the ...